Exciting Advancements in Treatment Options for MS Patients
A new clinical trial called HALT-MS has shown promising results in inducing the long term remission of relapsing-remitting multiple sclerosis, also known as MS. MS is an autoimmune disease where the body’s immune system attacks the central nervous system.
MS symptoms vary widely across patients, but can include speech and motor impairment, weakness, fatigue, and chronic pain. The most common type of MS is relapsing-remitting MS. This form of MS is depicted by periods of little to no symptoms followed by relapses which are likely to worsen over time, eventually turning into a progressive form of MS.
The HALT-MS study involved the procedure of collecting a patient’s stem cells, giving the patient a high dose of chemotherapy in order to deplete the immune system, and then returning the stem cells back into the body in order to rebuild the immune system.
The results of the study showed that 69 percent of trial participants went without experiencing progression or relapse of the disease. Other studies involving currently available MS drugs showed lower success rates. Five years after the study, many trial participants remained in remission. Some participants had even shown improvement in the area of mobility and other physical abilities once hindered from the disease. While more research is necessary, these are very promising results.
Dr. Shiva Gopal Vasishta is a neurologist located in Vorhees, New Jersey. He graduated from Government Medical College and completed his residency at Tufts Medical Center and Boston University Medical Center. Dr. Gopal Vasishta has been practicing medicine for almost 40 years.
Dr. Gopal Vasishta currently practices at Eastern Neurodiagnostic Associates and is affiliated with Kennedy University Hospital. He is one of 34 doctors at the hospital that specialize in neurology. In addition to neurology, Dr. Gopal Vasishta also specializes in Psychiatry.